Phase I/randomized phase II trial of TRC105 plus bevacizumab versus bevacizumab in recurrent glioblastoma: North Central Cancer Treatment Group N1174 (Alliance).
Evanthia GalanisS Keith AndersonErin TwohyNicholas A ButowskiAdilia HormigoDavid SchiffAntonio OmuroKurt A JaeckleShaji KumarTimothy J KaufmannSusan GeyerPriya U KumthekarJian CampianCaterina GianniniJan C BucknerPatrick Y WenPublished in: Neuro-oncology advances (2022)
TRC105 in combination with bevacizumab was well tolerated in patients with recurrent GBM, but no difference in efficacy was observed compared to bevacizumab monotherapy.